UK government's consultation on value-based pricing for pharmaceuticals imminent
This article was originally published in SRA
Executive Summary
The Department of Health in the UK will this week launch for consultation its plans for value-based pricing for pharmaceuticals, it has told Regulatory Affairs Pharma's sister publication Scrip Intelligence. The consultation will touch on the government's plans for the National Institute for Clinical Excellence, which will see the health technology assessment body cede to GPs (primary care physicians) its authority to definitively recommend whether or not to make certain drugs available on the National Health Service in England and Wales.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.